Becton, Dickinson and Co. | BDX - Cash And Equivalent

Stock Price
149.52
Daily Change
-0.70 -0.47%
Monthly
-3.34%
Yearly
-27.57%
Q2 Forecast
148.88

Becton, Dickinson and Co. reported $740M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
Agilent USD 1.76B 31M Dec/2025
Align Technology USD 1B 103.43M Sep/2025
AngioDynamics USD 41.64M 14.26M Sep/2025
Avanos Medical USD 89.8M 19.3M Dec/2025
Baxter International USD 1.97B 240M Dec/2025
Becton, Dickinson and Co. USD 740M 99M Dec/2025
Bio-Rad Laboratories USD 529.8M 134M Dec/2025
Boston Scientific USD 1.96B 690M Dec/2025
Cooper Companies USD 110.6M 14.3M Sep/2025
Danaher USD 5.7B 1.09B Mar/2026
Dentsply International USD 326M 37M Dec/2025
Dexcom USD 917.7M 918M Dec/2025
Edwards Lifesciences USD 2.4B 538M Mar/2026
Globus Medical USD 526.16M 154.39M Dec/2025
Insulet USD 716.1M 41.3M Dec/2025
Integra LifeSciences USD 235.05M 2.86M Dec/2025
Intuitive Surgical USD 7.98B 1.05B Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Masimo USD 312.3M 162.7M Sep/2025
Medtronic USD 1.15B 135M Dec/2025
Solventum Corp USD 878M 764M Dec/2025
Stryker USD 4.01B 755M Dec/2025
Tandem Diabetes Care USD 90.63M 1.31M Dec/2025
Teleflex USD 354M 100.3M Sep/2025
Terumo JPY 217.16B 12.86B Sep/2025
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Zimmer Biomet Holdings USD 591.9M 700.8M Dec/2025